FDA approves interchangeable biosimilar for multiple inflammatory diseases
FDA have approved biosimilar ustekinumab-auub (Wezlana by Amgen) in the USA. It is approved for the same indications, and considered interchangeable with Stelara (ustekinumab) for use in adults and children aged 6 years and over.
Source:
US Food and Drug Administration
SPS commentary:
Wezlana is not (yet) available in the UK. Several ustekinumab biosimilar products are in development globally.